




Q2 and H1 2017 Results

August 16th, 2017

Presented by:

René Goehrum
Chairman, President, and CEO




This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.


By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.


Sales, EBITDA and NIAT Quarter Ended June 30



Sales, EBITDA and NIAT Six Months Ended June 30



Pharmaceutical Sales By Quarter



- **Q2 2017 pharmaceutical sales of \$5.1 million increased 27% over Q2 2016**
 - Q2 2017 Canadian pharmaceutical sales of \$4.3 million increased 16% over Q2 2016
 - Q2 2017 vs. Q2 2016 Canadian sales volumes (units):
 - FeraMAX® 150 +8%
 - FeraMAX® Powder +28%
 - RepaGyn® +29%
 - Cathejell® Jelly 2% +32%
 - Q2 2017 International FeraMAX® sales of \$0.7 million increased 188% over Q2 2016
 - FeraMAX® shipments to one new international market in Q2 2017
 - International FeraMAX® sales have occurred in ten consecutive quarters
- **Q2 2017 Legacy business sales of \$0.6 million increased 54% over Q2 2016**

- **H1 2017 pharmaceutical sales of \$8.7 million increased 16% over H1 2016**
 - H1 2017 Canadian pharmaceutical sales of \$7.7 million increased 9% over H1 2016
 - H1 2017 vs. H1 2016 Canadian sales volumes (units):
 - FeraMAX[®] 150 +0.5%
 - » Secondary demand for product offsetting effect of reduction in Q1 wholesale trade inventory levels
 - FeraMAX[®] Powder +15%
 - RepaGyn[®] +32%
 - Cathejell[®] Jelly 2% +24%
 - H1 2017 International FeraMAX[®] sales of \$1.0 million increased 103% over H1 2016
- **H1 2017 Legacy business sales of \$0.7 million increased 23% over H1 2016**

- **H1 2017 Aguetant System® PFS sales (\$)** increased 2x vs. H1 2016
 - Atropine Sulphate re-launched Q1 2016
 - Phenylephrine Hydrochloride launched Q4 2016
 - Growth in line with management's expectations
- **Increased interest in Cysview® and endorsements from Canadian urological community**
 - Blue light cystoscopy cost-effectiveness study published in CUAJ in June 2017
 - 2 hospitals have adopted Cysview®
 - 2 additional hospitals have completed positive evaluations of Cysview®
 - Evaluations scheduled or in progress for 4 additional hospital sites
 - Adoption below management's expectations

- **March 2017: A 2nd Canadian hospital announces initiation of a Cysview[®] program**
- **April 2017: BioSyent extends in-license agreement for Cathejell[®] to 2024**
 - Since its 2012 launch, Cathejell[®] has posted double-digit year-over-year sales growth
- **May 2017: FeraMAX[®] named #1 recommended iron supplement brand in Canada for second consecutive year**
 - EnsembleIQ Healthcare Group annual survey of 2,505 Canadian physicians and pharmacists
 - % of both physicians and pharmacists surveyed naming FeraMAX[®] #1 in 2017 increased from 2016 survey results

Cathejell[®]

2% lidocaine hydrochloride jelly, USP



Growth driven by organic growth of existing portfolio **plus** incremental growth from new products and new international markets:

Existing product portfolio growth drivers

- FeraMAX[®]: Canada and International (existing markets)
- CYSVIEW[®]
- Cathejell[®] Jelly 2%
- RepaGyn[®]
- Aguettant System[®]

New products and new markets

- FeraMAX[®] International (Sales to new markets)
- 2 Cardiovascular Rx products; upon Health Canada approval
- Women's Health Rx product; upon Health Canada approval

New in-licensed products

- To be announced – active deal funnel

Balance Sheet Snapshot

BioSyent Inc.

Interim Unaudited Consolidated Statements of Financial Position

AS AT	June 30, 2017	December 31, 2016	% Change
ASSETS			
Trade and other receivables	\$ 2,705,117	\$ 1,941,177	39%
Inventory	1,482,113	1,560,050	-5%
Prepaid expenses and deposits	323,713	269,704	20%
Income tax recoverable	75,818	-	
Derivative asset	108,280	32,025	238%
Cash, cash equivalents and short-term investments	14,702,627	13,739,286	7%
Current Assets	19,397,668	17,542,242	11%
Equipment	305,248	291,331	5%
Intangible assets	1,508,282	1,277,235	18%
Loans receivable	391,500	-	
Deferred tax asset	119,567	137,375	-13%
TOTAL NON CURRENT ASSETS	2,324,597	1,705,941	36%
TOTAL ASSETS	\$ 21,722,265	\$ 19,248,183	13%
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities	\$ 2,163,172	\$ 2,358,226	-8%
Deferred tax liability	199,760	163,241	22%
Long term debt	-	-	0%
Total Equity	19,359,333	16,726,716	16%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 21,722,265	\$ 19,248,183	13%


Working Capital of
\$17,234,496
+14% from Dec. 31, 2016

Cash and ST investments
of \$14,702,627
+7% from Dec. 31, 2016


\$391,500 in loan proceeds
advanced under MSLP

Zero Debt

June 30 Cash Balance and H1 Cash Generation (“CG”)



Return on Equity (“ROE”)



Quarter	NIAT	Diluted EPS	
Q2 2017	\$1,552,918	\$ 0.11	\$0.33
Q1 2017	\$ 901,556	\$ 0.06	
Q4 2016	\$1,094,822	\$ 0.08	
Q3 2016	\$1,247,380	\$ 0.08	
Q2 2016	\$1,015,449	\$ 0.07	\$0.27
Q1 2016	\$ 951,854	\$ 0.07	
Q4 2015	\$ 762,602	\$ 0.05	
Q3 2015	\$1,188,536	\$ 0.08	

TTM EPS Growth +22%



Stock Information

August 15, 2017

Exchange & Trading Symbol:
Aug 15, 2017 closing stock price (CAD)
52 Week Hi / Low:
Current Shares:
Warrants:
Options:
Fully Diluted:
P/E Ratio (TTM):
P/B Ratio:

TSXV: RX
\$8.60
\$8.82 / \$6.90
14,476,353
0
172,506
14,648,859
26.26
6.43

Thank you

www.BioSyent.com

www.sedar.com

www.tmxmoney.com

www.BioSyentPFS-System.ca

www.Cathejell.ca

www.CYSVIEW.ca

www.FeraMAX.com

www.Proktis-M.ca

www.RepaGyn.ca